Covered recipient · General Payments record
JOSIAH ZACHARY
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2020–2024
$892.96
- Reported across 42 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $764.94 | 35 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $327.18 | 4 |
| ABBVIE INC. | $189.05 | 15 |
| Corium, Inc. | $101.46 | 8 |
| Lilly USA, LLC | $32.33 | 2 |
| Ultragenyx Pharmaceutical Inc. | $25.77 | 1 |
| Otsuka America Pharmaceutical, Inc. | $21.39 | 1 |
| Ardelyx, Inc. | $19.80 | 1 |
| Novo Nordisk AS | $16.83 | 1 |
| Bayer HealthCare Pharmaceuticals Inc. | $16.24 | 1 |
| GlaxoSmithKline, LLC. | $14.89 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (35)
Sorted by paying entity, then date · as published by CMS
Program year 2024 202020222023
Record-level detail is published for PY2024; earlier years are summarised in
“By program year”.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $14.33 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386458 | CMS |
| ABBVIE INC. | $7.55 | 02/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386460 | CMS |
| ABBVIE INC. | $12.74 | 02/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386462 | CMS |
| ABBVIE INC. | $15.36 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386464 | CMS |
| ABBVIE INC. | $21.68 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386466 | CMS |
| ABBVIE INC. | $21.20 | 06/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386468 | CMS |
| ABBVIE INC. | $3.33 | 06/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386470 | CMS |
| ABBVIE INC. | $8.72 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386472 | CMS |
| ABBVIE INC. | $11.22 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386474 | CMS |
| ABBVIE INC. | $14.80 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386476 | CMS |
| ABBVIE INC. | $17.19 | 10/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386478 | CMS |
| ABBVIE INC. | $12.84 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386480 | CMS |
| ABBVIE INC. | $5.70 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386482 | CMS |
| ABBVIE INC. | $10.21 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386484 | CMS |
| ABBVIE INC. | $12.18 | 11/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106386486 | CMS |
| Ardelyx, Inc. | $19.80 | 12/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146715443 | CMS |
| AstraZeneca Pharmaceuticals LP | $69.10 | 04/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104662483 | CMS |
| AstraZeneca Pharmaceuticals LP | $120.00 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104428129 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.09 | 10/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104240887 | CMS |
| AstraZeneca Pharmaceuticals LP | $124.99 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105866172 | CMS |
| Bayer Healthcare Pharmaceuticals Inc. | $16.24 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1086113870 | CMS |
| Corium, LLC | $24.93 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100083594 | CMS |
| Corium, LLC | $4.60 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100133322 | CMS |
| Corium, LLC | $1.38 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100137311 | CMS |
| Corium, LLC | $2.04 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100141473 | CMS |
| Corium, LLC | $8.09 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100151419 | CMS |
| Corium, LLC | $28.24 | 05/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100197934 | CMS |
| Corium, LLC | $2.41 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100141949 | CMS |
| Corium, LLC | $29.77 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100200489 | CMS |
| GlaxoSmithKline, LLC. | $14.89 | 07/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1115965754 | CMS |
| Lilly USA, LLC | $17.43 | 06/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135087246 | CMS |
| Lilly USA, LLC | $14.90 | 08/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135088675 | CMS |
| Novo Nordisk Inc | $16.83 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096740620 | CMS |
| Otsuka America Pharmaceutical, Inc. | $21.39 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1119008343 | CMS |
| Ultragenyx Pharmaceutical Inc. | $25.77 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153280317 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2020, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.